236 related articles for article (PubMed ID: 32762731)
1. Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models.
Vitale F; Ortolan J; Volpe BT; Marambaud P; Giliberto L; d'Abramo C
Acta Neuropathol Commun; 2020 Aug; 8(1):126. PubMed ID: 32762731
[TBL] [Abstract][Full Text] [Related]
2. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
3. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease.
Wang YJ; Pollard A; Zhong JH; Dong XY; Wu XB; Zhou HD; Zhou XF
Neurobiol Aging; 2009 Mar; 30(3):364-76. PubMed ID: 17686552
[TBL] [Abstract][Full Text] [Related]
5. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
6. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
[TBL] [Abstract][Full Text] [Related]
7. Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Goodwin MS; Sinyavskaya O; Burg F; O'Neal V; Ceballos-Diaz C; Cruz PE; Lewis J; Giasson BI; Davies P; Golde TE; Levites Y
Mol Ther; 2021 Feb; 29(2):859-872. PubMed ID: 33128896
[TBL] [Abstract][Full Text] [Related]
8. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
[TBL] [Abstract][Full Text] [Related]
9. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease.
Wang YJ; Gao CY; Yang M; Liu XH; Sun Y; Pollard A; Dong XY; Wu XB; Zhong JH; Zhou HD; Zhou XF
Brain Behav Immun; 2010 Nov; 24(8):1281-93. PubMed ID: 20595065
[TBL] [Abstract][Full Text] [Related]
11. Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease.
Gibbons GS; Kim SJ; Wu Q; Riddle DM; Leight SN; Changolkar L; Xu H; Meymand ES; O'Reilly M; Zhang B; Brunden KR; Trojanowski JQ; Lee VMY
Mol Neurodegener; 2020 Nov; 15(1):64. PubMed ID: 33148293
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular delivery of p75NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer's disease-like pathologies in APP/PS1 transgenic mice.
Wang QH; Wang YR; Zhang T; Jiao SS; Liu YH; Zeng F; Li J; Yao XQ; Zhou HD; Zhou XF; Wang YJ
J Neurochem; 2016 Jul; 138(1):163-73. PubMed ID: 26991827
[TBL] [Abstract][Full Text] [Related]
13. The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease.
Sun Y; Guo Y; Feng X; Jia M; Ai N; Dong Y; Zheng Y; Fu L; Yu B; Zhang H; Wu J; Yu X; Wu H; Kong W
J Neuroinflammation; 2020 Feb; 17(1):72. PubMed ID: 32093751
[TBL] [Abstract][Full Text] [Related]
14. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
15. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
16. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
17. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
18. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
20. Passive immunization inhibits tau phosphorylation and improves recognition learning and memory in 3xTg-AD mice.
Li L; Miao J; Jiang Y; Dai CL; Iqbal K; Liu F; Chu D
Exp Neurol; 2023 Apr; 362():114337. PubMed ID: 36717015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
